Holistic integrative oncology最新文献

Advances in plasma metabolomics detection technology and its clinical applications in lung cancer and other malignancies. 血浆代谢组学检测技术及其在肺癌等恶性肿瘤中的临床应用进展。

Holistic integrative oncology Pub Date : 2026-01-01 Epub Date: 2026-04-24 DOI: 10.1007/s44178-026-00248-x

Yue He, Juntong Guo, Pufan Gao, Zifan Li, Wenxiang Wang, Kezhong Chen

{"title":"Advances in plasma metabolomics detection technology and its clinical applications in lung cancer and other malignancies.","authors":"Yue He, Juntong Guo, Pufan Gao, Zifan Li, Wenxiang Wang, Kezhong Chen","doi":"10.1007/s44178-026-00248-x","DOIUrl":"10.1007/s44178-026-00248-x","url":null,"abstract":"Metabolic reprogramming is a fundamental hallmark distinguishing tumor cells from their normal counterparts. This process leads to pronounced alterations in the types and concentrations of metabolites present in the bodily fluids of cancer patients via liquid biopsy approaches. Plasma and serum, owing to their minimally invasive collection, repeatability, and ability to reflect systemic metabolic status, have emerged as optimal sample types for clinical metabolomics. These metabolic changes serve as valuable indicators for inferring disease progression and predicting patient prognosis. Lung cancer, particularly non-small cell lung cancer (NSCLC), with its high global incidence and mortality, represents a critical area where plasma metabolomics can address unmet clinical needs in prognostic prediction and therapeutic stratification. This review focuses primarily on lung cancer. However, the scarcity of studies investigating the prognostic value of metabolite alterations in lung cancer promoted the inclusion of research from other malignancies as well. This review first summarizes the current liquid biopsy metabolomics detection technologies and associated biological materials, followed by an overview of tumor-related metabolic pathway alterations. It then discusses the clinical applications of these principles in prognostic prediction and therapeutic evaluation. The aim is to provide a comprehensive overview and inspire future research directions in this field.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"5 1","pages":"33"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147791072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CACA Technical guidelines for holistic integrative management of cancer —— genetic testing CACA癌症整体综合管理技术指南——基因检测

Holistic integrative oncology Pub Date : 2025-03-17 DOI: 10.1007/s44178-025-00149-5

Bing Wei, Jinliang Xing, Xiaoyan Zhou, Jie Ma, Nengtai Ouyang, Jinpu Yu, Jinyan Huang, Hongxue Meng, Dan Su, Hongle Li

{"title":"CACA Technical guidelines for holistic integrative management of cancer —— genetic testing","authors":"Bing Wei, Jinliang Xing, Xiaoyan Zhou, Jie Ma, Nengtai Ouyang, Jinpu Yu, Jinyan Huang, Hongxue Meng, Dan Su, Hongle Li","doi":"10.1007/s44178-025-00149-5","DOIUrl":"https://doi.org/10.1007/s44178-025-00149-5","url":null,"abstract":"Abstract Cancer management increasingly benefits from advances in genetic testing, offering new opportunities for prevention, diagnosis, and personalized treatment. This guideline, developed by the Committee of Cancer Genetic Diagnosis of the Chinese Anti-Cancer Association (CACA), provides a comprehensive framework for integrating genetic testing into a holistic approach to cancer care. Addressing key aspects of genetic testing—including patient selection, testing protocols, interpretation of genetic results, and integration into treatment plans—this document is designed to support clinicians in making informed decisions that align with each patient’s unique genetic profile and overall well-being. By emphasizing evidence-based practices and incorporating input from experts in oncology and genetics, these guidelines aim to optimize the effectiveness of genetic testing in cancer care, ultimately enhancing outcomes and quality of life for patients. Our approach promotes the use of genetic insights as a complement to integrative oncology, underscoring the potential of genetic testing to improve holistic management strategies across various cancer types.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s44178-025-00149-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147900503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development. 神经内分泌前列腺癌发展中的转录因子动力学。

Holistic integrative oncology Pub Date : 2025-01-01 Epub Date: 2025-10-24 DOI: 10.1007/s44178-025-00197-x

Yu Wang, Yuzhuo Wang

{"title":"Transcription Factor Dynamics in Neuroendocrine Prostate Cancer Development.","authors":"Yu Wang, Yuzhuo Wang","doi":"10.1007/s44178-025-00197-x","DOIUrl":"10.1007/s44178-025-00197-x","url":null,"abstract":"Treatment-induced neuroendocrine prostate cancer (NEPC) represents a lethal evolution of prostate adenocarcinoma under androgen receptor pathway inhibition, posing a significant clinical challenge. In a recent landmark study, Wang et al. introduced an innovative internal Z-score based approach to comprehensively characterize the transcription factor (TF) landscape in prostate cancer progression, uncovering distinct TF profiles associated with adenocarcinoma and NEPC lineages. Notably, the study proposes a three-phase model of NEPC transdifferentiation-comprising de-differentiation, dormancy, and re-differentiation-revealing dynamic shifts in TF expression that underpin lineage plasticity and therapeutic resistance. This commentary critically evaluates the methodological advancements, the functional significance of the identified TF signatures, and the broader implications of these findings for developing novel therapeutic strategies. By delineating the molecular events driving the transition from androgen receptor (AR)-dependent adenocarcinoma to treatment-resistant NEPC, this work underscores the potential of targeting early and dormant phases of transdifferentiation to improve patient outcomes.","PeriodicalId":73245,"journal":{"name":"Holistic integrative oncology","volume":"4 1","pages":"65"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12552323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing Australia’s first national cancer control plan to shape Australian cancer control policy for the next decade and beyond 实施澳大利亚首个国家癌症控制计划，制定澳大利亚未来十年及以后的癌症控制政策

Holistic integrative oncology Pub Date : 2024-07-24 DOI: 10.1007/s44178-024-00099-4

Daniel Chaji, Lisa Malloy, David Meredyth, V. Milch, Cindy Toms, Claire Howlett, Dorothy Keefe

引用次数: 0

Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis 目前治疗高体积转移性激素敏感性前列腺癌的临床疗效：系统综述和网络荟萃分析

Holistic integrative oncology Pub Date : 2024-07-22 DOI: 10.1007/s44178-024-00106-8

Yuxuan Tian, Zhifu Liu, Y. Mulati, K. Yao, Jie Jin, Zhisong He, Yu Fan

引用次数: 0

Review of management of primary oesophagogastric cancers in East Asian versus Western countries 东亚与西方国家原发性食管胃癌管理回顾

Holistic integrative oncology Pub Date : 2024-07-17 DOI: 10.1007/s44178-024-00108-6

Raja Chaganti, Mark Wong

引用次数: 0

A comprehensive analysis and comparison of lipid metabolism and inflammatory indices in patients with benign prostatic hyperplasia and prostate cancer 良性前列腺增生和前列腺癌患者脂质代谢和炎症指数的综合分析与比较

Holistic integrative oncology Pub Date : 2024-07-17 DOI: 10.1007/s44178-024-00105-9

Lei Xu, Yi Xu, Shouzhen Chen, Benkang Shi

引用次数: 0

The evolution of the multidisciplinary tumor board in orthopedic oncology: from its historical roots to its future potential 骨科肿瘤学多学科肿瘤委员会的演变：从历史渊源到未来潜力

Holistic integrative oncology Pub Date : 2024-07-09 DOI: 10.1007/s44178-024-00107-7

Barlas Goker, Mary Shea, Ranxin Zhang, Jichuan Wang, A. Ferrena, Sung-Suk Chae, Hasibagan Borjihan, Rui Yang, Bang H. Hoang, David S Geller, Beverly A. Thornhill, Nogah Haramati, Chuanyong Lu, Javier A. Laurini, Esperanza Villanueva-Siles, E. Mardakhaev

引用次数: 0

Guidelines for holistic integrative management of pancreatic cancer 胰腺癌整体综合治疗指南

Holistic integrative oncology Pub Date : 2024-07-08 DOI: 10.1007/s44178-024-00097-6

Xianjun Yu

引用次数: 0

Recent advances in the treatment of pancreatic cancer 胰腺癌治疗的最新进展

Holistic integrative oncology Pub Date : 2024-07-02 DOI: 10.1007/s44178-024-00089-6

Yongsu Ma, Fusheng Zhang, Yinmo Yang

引用次数: 0